The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia/reperfusion injury
Open accessAbstract
Acute activation of the serine-threonine kinase Akt is cardioprotective and reduces both infarction and dysfunction after ischemia/reperfusion injury (IRI). However, less is known about the chronic effects of Akt activation in the heart, and, paradoxically, Akt is activated in samples from patients with chronic heart failure. We generated Tg mice with cardiac-specific expression of either activated (myristoylated [myr]) or dominant-negative (dn) Akt and assessed their response to IRI in an ex vivo model. While dn-Akt hearts demonstrated a moderate reduction in functional recovery after IRI, no function was restored in any of the myr-Akt-Tg hearts. Moreover, infarcts were dramatically larger in myr-Akt-Tg hearts. Biochemical analyses demonstrated that chronic Akt activation induces feedback inhibition of PI3K activity through both proteasome-dependent degradation of insulin receptor substrate-1 (IRS-1) and inhibition of transcription of IRS-1 as well as that of IRS-2. To test the functional significance of these signaling changes, we performed in vivo cardiac gene transfer with constitutively active PI3K in myr-Akt-Tg mice. Restoration of PI3K rescued function and reduced injury after IRI. These data demonstrate that PI3K-dependent but Akt-independent effectors are required for full cardioprotection and suggest a mechanism by which chronic Akt activation can become maladaptive.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591 · cited 1×
“Since Akt1 activates eNOS (40, 41), NO-mediated inhibition of leukocyte adhesion may mitigate IRI (42) in vivo despite a moderate reduction in the level of IRS-1 in the TG20 line.”
BackgroundAguirre, V., Uchida, T., Yenush, L., Davis, R., & White, M. F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.9047 · Cited by 1,487 · cited 1×
“Prior studies in other systems have also demonstrated that serine or threonine phosphorylation of IRS-1 mediated by a variety of kinases including inhibitor of kB kinase (IKK) (28, 29), PKC (30, 31), JNK (32), p70S6 kinase (33), and Akt (21) can inhibit PI3K activation through either reduced IRS-1/PI3K association or…”
BackgroundAlternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene
Araki, E., Lipes, M. A., Patti, M.-E., Brüning, J. C., Haag III, B., Johnson, R. S., & Kahn, C. R. (1994) · Nature · doi:10.1038/372186a0 · Cited by 1,252 · cited 3×
“IRS-2 can also activate PI3K and may be particularly important in the setting of reduced IRS-1 levels (13).”
BackgroundInfluentialPrevention of fat-induced insulin resistance by salicylate
Kim, J. K., Kim, Y.-J., Fillmore, J. J., Chen, Y., Moore, I., Lee, J., Yuan, M., Li, Z. W., Karin, M., Perret, P., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11559 · Cited by 737
Protein Kinase Bα/Akt1 Regulates Placental Development and Fetal Growth
Yang, Z.-Z., Tschopp, O., Hemmings-Mieszczak, M., Feng, J., Brodbeck, D., Perentes, E., & Hemmings, B. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302847200 · Cited by 384
Self-citationTranscriptional effects of chronic Akt activation in the heart
Cook, S. A., Matsui, T., Li, L., & Rosenzweig, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201462200 · Cited by 199
Self-citation
Cited by
Kempf, T., Eden, M., Strelau, J., Naguib, M., Willenbockel, C., Tongers, J., Heineke, J., Kotlarz, D., Xu, J., Molkentin, J. D., et al. (2006) · Circulation Research · doi:10.1161/01.res.0000202805.73038.48 · Cited by 651
Vakhrusheva, O., Smolka, C., Gajawada, P., Kostin, S., Boettger, T., Kubin, T., Braun, T., & Bober, E. (2008) · Circulation Research · doi:10.1161/circresaha.107.164558 · Cited by 637
Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction
Yan, X., Anzai, A., Katsumata, Y., Matsuhashi, T., Ito, K., Endo, J., Yamamoto, T., Takeshima, A., Shinmura, K., Shen, W., et al. (2013) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2013.04.023 · Cited by 610
Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo
Chen, J., Somanath, P. R., Razorenova, O., Chen, W. S., Hay, N., Bornstein, P., & Byzova, T. V. (2005) · Nature Medicine · doi:10.1038/nm1307 · Cited by 456
The critical role of Akt in cardiovascular function
Abeyrathna, P., & Su, Y. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.05.008 · Cited by 423
C/EBPβ Controls Exercise-Induced Cardiac Growth and Protects against Pathological Cardiac Remodeling
Boström, P., Mann, N., Wu, J., Quintero, P. A., Plovie, E. R., Panáková, D., Gupta, R. K., Xiao, C., MacRae, C. A., Rosenzweig, A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.11.036 · Cited by 411
“We thus investigated the connection of this pathway to C/EBPb using both forced expression of wild-type AKT1 and a dominant-negative AKT1 (Nagoshi et al., 2005).”
Self-citationAMPK inhibition in health and disease
Viollet, B., Horman, S., Leclerc, J., Lantier, L., Foretz, M., Billaud, M., Giri, S., & Andreelli, F. (2010) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2010.488215 · Cited by 383
Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway
Shiojima, I., & Walsh, K. (2006) · Genes & Development · doi:10.1101/gad.1492806 · Cited by 356
Zordoky, B. N. M., Robertson, I. M., & Dyck, J. R. B. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.10.016 · Cited by 335
Akt1 in Endothelial Cell and Angiogenesis
Somanath, P. R., Razorenova, O. V., Chen, J., & Byzova, T. V. (2006) · Cell Cycle · doi:10.4161/cc.5.5.2538 · Cited by 295
Ni, Y. G., Wang, N., Cao, D. J., Sachan, N., Morris, D. J., Gerard, R. D., Kuro-o, M., Rothermel, B. A., & Hill, J. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610290104 · Cited by 279
Role of PI3K/Akt signaling pathway in cardiac fibrosis
Qin, W., Cao, L., & Massey, I. Y. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04219-w · Cited by 277
The Prostanoid EP4 Receptor and Its Signaling Pathway
Yokoyama, U., Iwatsubo, K., Umemura, M., Fujita, T., & Ishikawa, Y. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007195 · Cited by 264
Myostatin Inhibits IGF-I-Induced Myotube Hypertrophy through Akt
Morissette, M. R., Cook, S. A., Buranasombati, C., Rosenberg, M. A., & Rosenzweig, A. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00043.2009 · Cited by 231
Self-citationHua, Y., Zhang, Y., Ceylan-Isik, A. F., Wold, L. E., Nunn, J. M., & Ren, J. (2011) · Basic Research in Cardiology · doi:10.1007/s00395-011-0222-8 · Cited by 178
Myostatin activation in patients with advanced heart failure and after mechanical unloading
George, I., Bish, L. T., Kamalakkannan, G., Petrilli, C. M., Oz, M. C., Naka, Y., Lee Sweeney, H., & Maybaum, S. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq039 · Cited by 136
Leosco, D., Rengo, G., Iaccarino, G., Golino, L., Marchese, M., Fortunato, F., Zincarelli, C., Sanzari, E., Ciccarelli, M., Galasso, G., et al. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvm109 · Cited by 131
Metadata
- Authors
- Nagoshi, T., Matsui, T., Aoyama, T., Leri, A., Anversa, P., Li, L., Ogawa, W., del Monte, F., Gwathmey, J. K., Grazette, L., Hemmings, B., Kass, D. A., Champion, H. C., & Rosenzweig, A.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-08-01
- Volume
- 115
- Issue
- 8
- Pages
- 2128-2138
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2142980653
- Cited by
- 230
- References
- 7
- FWCI
- 12.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.